Cancer types in which the expression of both GRHL2 and S100A10 is simultaneously increased include hepatocellular carcinoma, non-small-cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma [9,26]. Here, S100A10 is linked to cancer.